Who are Tavneos's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tavneos.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ccx168.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tavneos — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tavneos (CCX168) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement 5a Receptor Antagonist. Area: Rare Disease.

discontinued Complement 5a Receptor Antagonist C5a anaphylatoxin chemotactic receptor 1 Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

Tavneos (CCX168) — Chemocentryx. Tavneos blocks the action of a chemical called C5a, which is involved in inflammation and damage to blood vessels.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tavneos TARGET	CCX168	Chemocentryx	discontinued	Complement 5a Receptor Antagonist	C5a anaphylatoxin chemotactic receptor 1	2021-01-01
Tavneos	AVACOPAN	Chemocentryx	marketed	Complement 5a Receptor Antagonist [EPC]	C5a anaphylatoxin chemotactic receptor 1	2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-12-21 — Tavneos · 8906938 · US
2031-02-03 — Tavneos · 8445515 · US
2041-05-29 — Tavneos · 11603356 · US

Sponsor landscape (Complement 5a Receptor Antagonist class)

Chemocentryx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tavneos — Competitive Intelligence Brief. https://druglandscape.com/ci/ccx168. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing